Article content material
WINNIPEG, Manitoba, Oct. 23, 2024 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) broadcasts that it’s donating 2,000 ounces of revyve™ Antimicrobial Wound Gel to the Ukraine medical reduction effort.
The product shall be used to help within the therapeutic of extreme and continual wounds that tens of hundreds of Ukrainian casualties have suffered because of the devasting results of warfare.
“I’m humbled by the prospect of aiding the folks of Ukraine of their time of want,” stated Marc Edwards, President & CEO. “Now we have a chance to make a distinction within the remedy of wounds suffered on this theater of operations. I do know that Kane’s revyve™ wound gel shall be well-received by the federal government of Ukraine and directed to the place it’s most urgently required.”
Article content material
Marc Edwards, Kane’s President and CEO, met with Ihor Kuzin, Ukraine’s Deputy Minister of Well being, Ruslana Velychko-Trufoniuk, Ukraine’s Deputy Minister of Veteran Affairs and Yevheniia Smirnova, Ukraine’s Deputy Minister of Schooling and Science whereas attending a operate on the Embassy of Ukraine in Canada on October 22, 2024.
“The necessity far outweighs our present monetary capabilities right now, so we shall be working with the Ukrainian authorities to formally request that revyve™ Antimicrobial Wound Gel be included in each the Canadian and US reduction packages,” Marc Edwards defined additional.
About Kane Biotech
Kane Biotech Inc. is a biotechnology firm engaged within the analysis, improvement and commercialization of applied sciences and merchandise that stop and take away microbial biofilms. Kane has a portfolio of biotechnologies, mental property (68 patents and patents pending, commerce secrets and techniques and emblems) and merchandise developed by Kane’s personal biofilm analysis experience and bought from main analysis establishments. DispersinB®, coactiv+™, coactiv+®, DermaKB™, DermaKB Biofilm™, and revyve™ are emblems of Kane Biotech Inc. Kane is listed on the TSX Enterprise Alternate beneath the image “KNE” and on the OTCQB Enterprise Market beneath the image “KNBIF”.
Article content material
For extra data:
Neither TSX Enterprise Alternate nor its Regulation Companies Supplier (as that time period is outlined in insurance policies of the TSX Enterprise Alternate) accepts duty for the adequacy or accuracy of this launch.
Warning Concerning Ahead-Wanting Data
This press launch comprises sure statements relating to Kane Biotech Inc. that represent forward-looking data beneath relevant securities legislation. These statements mirror administration’s present beliefs and are based mostly on data at present accessible to administration. Sure materials elements or assumptions are utilized in making forward-looking statements, and precise outcomes might differ materially from these expressed or implied in such statements. These dangers and uncertainties embody, however usually are not restricted to, dangers regarding Kane’s: (a) monetary situation, together with lack of great revenues to this point and reliance on fairness and different financing; (b) enterprise, together with its early stage of improvement, authorities regulation, market acceptance for its merchandise, fast technological change and dependence on key personnel; (c) mental property together with the flexibility of Kane to guard its mental property and dependence on its strategic companions; and (d) capital construction, together with its lack of dividends on its widespread shares, volatility of the market value of its widespread shares and public firm prices. Additional details about these and different dangers and uncertainties may be discovered within the disclosure paperwork filed by Kane with relevant securities regulatory authorities, accessible at www.sedarplus.ca. Kane cautions that the foregoing record of things that will have an effect on future outcomes just isn’t exhaustive.
Share this text in your social community
